Vaxxinity Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Mei Hu

Chief Executive Officer (CEO)

US$1.4m

Compensación total

Porcentaje del salario del CEO	22.6%
Permanencia del CEO	10.8yrs
Participación del CEO	4.4%
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	3.3yrs

Actualizaciones recientes de la dirección

Recent updates

A Look At The Intrinsic Value Of Vaxxinity, Inc. (NASDAQ:VAXX)

Jan 08

Vaxxinity initiates rolling submission for its COVID-19 shot with UK's drug regulator

Sep 12

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Mei Hu en comparación con los beneficios de Vaxxinity?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$1m	US$308k	-US$57m
Sep 30 2023	n/a	n/a	-US$66m
Jun 30 2023	n/a	n/a	-US$72m
Mar 31 2023	n/a	n/a	-US$75m
Dec 31 2022	US$532k	US$400k	-US$75m
Sep 30 2022	n/a	n/a	-US$103m
Jun 30 2022	n/a	n/a	-US$114m
Mar 31 2022	n/a	n/a	-US$123m
Dec 31 2021	US$13m	US$400k	-US$137m
Sep 30 2021	n/a	n/a	-US$102m
Jun 30 2021	n/a	n/a	-US$88m
Mar 31 2021	n/a	n/a	-US$68m
Dec 31 2020	US$348k	US$335k	-US$40m

Compensación vs. Mercado: La compensación total de Mei($USD1.36M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD646.00K).

Compensación vs. Ingresos: La compensación de Mei ha aumentado mientras la empresa no es rentable.

CEO

Mei Hu (41 yo)

10.8yrs

Permanencia

US$1,360,331

Compensación

Ms. Mei Mei Hu, J.D., serves as Chief Executive Officer of Vaxxinity, Inc. and has been its President has been its Director since 2014 and served as its President until June 2022. She Co-Founded Vaxxinity,...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Louis Reese	Co-Founder & Executive Chairman of the Board	10.2yrs	US$1.29m	3.13% $ 397.3
Mei Hu	Co-Founder	no data	US$1.36m	4.35% $ 551.9
Sumita Ray	Chief Legal	1.1yrs	US$823.41k	sin datos
Jason Pesile	Chief Accounting Officer	less than a year	sin datos	sin datos
Jean-Cosme Dodart	Chief Scientific Officer	less than a year	sin datos	sin datos
Mark Joinnides	Chief of Staff	no data	sin datos	sin datos
Manal Morsy	Chief Regulatory Officer	less than a year	sin datos	sin datos

0.8yrs

Permanencia media

46yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de VAXX no se considera experimentado ( 0.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Louis Reese	Co-Founder & Executive Chairman of the Board	10.2yrs	US$1.29m	3.13% $ 397.3
Mei Hu	Co-Founder	10.8yrs	US$1.36m	4.35% $ 551.9
George Hornig	Independent Director	2.8yrs	US$264.15k	0% $ 0
Peter Diamandis	Non-Employee Independent Director	3.7yrs	US$233.94k	1.59% $ 202.0
Eric Reiman	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jeffrey Cummings	Member of Scientific Advisory Board	no data	sin datos	sin datos
Stanley Plotkin	Member of Scientific Advisory Board	no data	sin datos	sin datos
Gabrielle Toledano	Independent Director	1.8yrs	US$259.99k	0% $ 0
Richard Mohs	Member of Scientific Advisory Board	no data	sin datos	sin datos
Brad Boeve	Member of Scientific Advisory Board	no data	sin datos	sin datos
Nick Fox	Member of Scientific Advisory Board	no data	sin datos	sin datos
Landon Ogilvie	Lead Independent Director	1.8yrs	US$270.62k	0.026% $ 3.3

3.3yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de VAXX se considera experimentada (3.3 años de antigüedad promedio).

Vaxxinity Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Vaxxinity, Inc. Announces Resignation of Katherine Eade from the Board of Directors

High number of new directors

Vaxxinity, Inc. Announces Executive Changes

Vaxxinity, Inc. Announces Executive Changes

Non-Employee Independent Director exercised options to buy US$1.0m worth of stock.

Less than half of directors are independent

Recent updates

Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine

Vaxxinity Files Form 15

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024

Vaxxinity, Inc. Receives A Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Vaxxinity, Inc. Announces the Publication of Data from Multiple Non-Human Primate Studies

Vaxxinity, Inc. to Present Data from UB-312 Program in Parkinson's Disease at International Conference on Alzheimer's and Parkinson's Diseases and Related Neurolog Disorders

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Vaxxinity, Inc. Announces Resignation of Katherine Eade from the Board of Directors

New major risk - Financial position

High number of new directors

Vaxxinity, Inc. Announces Executive Changes

Vaxxinity, Inc. Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer's Disease

New minor risk - Financial position

Vaxxinity, Inc. Announces Executive Changes

Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson's Disease

Non-Employee Independent Director exercised options to buy US$1.0m worth of stock.

Less than half of directors are independent

Vaxxinity, Inc. Announces the Relocation of its Corporate Headquarters

A Look At The Intrinsic Value Of Vaxxinity, Inc. (NASDAQ:VAXX)

Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612

Price target decreased to US$13.50

Less than half of directors are independent

Price target decreased to US$13.50

Vaxxinity Completes Enrollment in Pivotal Phase 3 Clinical Trial of UB-612 COVID-19 Vaccine Heterologous Booster Candidate and Initiates Rolling Submission for Provisional Approval in Australia

Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine

Vaxxinity initiates rolling submission for its COVID-19 shot with UK's drug regulator

Vaxxinity's Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non Human Primates

Vaxxinity, Inc. Presents Preclinical Data on Tau Vaccine Candidates At the 2022 Alzheimer's Association International Conference

Less than half of directors are independent

The Coalition for Epidemic Preparedness Innovations to Co-Fund Vaxxinity, Inc.'s Pivotal Phase 3 UB-612 Heterologous Booster Trial to Combat SARS-CoV-2 variants

Less than half of directors are independent

Vaxxinity, Inc. Announces First Participant Dosed in Phase 3 Study of Next-Generation Covid-19 Vaccine Booster

Vaxxinity’s COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern

Vaxxinity, Inc. Announces First Parkinson’s Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Non-Employee Independent Director recently bought US$63k worth of stock

Co-Founder & Executive Chairman recently bought US$242k worth of stock

Less than half of directors are independent

Second quarter 2021 earnings released: US$0.39 loss per share

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad